₹372.20
+₹12.15 (+3.37%)
Closed · As of 26 Aug 3:30 pm
Mkt Cap
₹10,177 Cr
P/E
-28.88
ROE
-46.73%
ROCE
-45.42%
About Suven Life Sciences Ltd
Suven Life Sciences is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. The goal is to be the leading biopharmaceutical company focused on the treatment of dementia, a condition characterized by a significant decline in mental capacity and impaired daily function.
Founded
1989
CEO
Venkateswarlu Jasti
Employees
187
HQ
Hyderabad, India
About Suven Life Sciences Ltd
Suven Life Sciences is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. The goal is to be the leading biopharmaceutical company focused on the treatment of dementia, a condition characterized by a significant decline in mental capacity and impaired daily function.
Founded:1989
CEO:Venkateswarlu Jasti
Employees:187
HQ:Hyderabad, India
Finished Products
1Service Income
₹18.35CrRaw Materials
No raw materials reported
This company hasn’t disclosed any raw materials breakdown.
Price Performance & Market EventsPrice Performance
Loading chart data…
Key Metrics
Trading & valuation snapshot
52W High
₹394
52W Low
₹124
Volume542.23K
Avg VolumeN/A
Beta1.21
Dividend Yield0.00%
Key Financial Ratios
Profitability, leverage & efficiency at a glance
P/E Ratio
-28.88x
Valuation
P/B Ratio
14.86x
Valuation
EPS
₹-12.47
Valuation
Dividend Yield
0.00%
Valuation
ROE
-46.73%
Profitability
ROCE
-45.42%
Profitability
Revenue by Segment
Contribution & growth by business line
Manufacturing (CRAMS)
+2.8%92.5%
₹613.87 Cr
Services (DDDSS)
+75.8%7.5%
₹49.88 Cr
Geographical Revenue Split
Domestic vs international exposure
Domestic
71.1%
International
28.9%
INDIA71.1%
OTHERS22.7%
EUROPE5.3%
U S A0.9%
Strategic Relations
Collaborations, joint ventures & subsidiaries
D
Dupont
United States
0.00% stakeB
Borregaard Synthesis Inc
United States
0.00% stakeE
Eli Lilly and Company
United States
0.00% stakeForensic Metrics
Financial health & earnings-quality indicators
Revenue Quality
N/A
Days Sales Outstanding
Leverage
0.03x
Debt-to-Equity
Earnings Quality
N/A
Cash Conversion Ratio
Efficiency
N/A
Asset Turnover
Earnings Quality
N/A
Accruals Ratio
Profitability
N/A
Gross Margin
Growth
-15.3%
Sales Growth
These metrics are derived from available financial disclosures and market data. Use them together with company filings and qualitative analysis before making decisions.